Paul Kwo, M.D., Indiana University School of Medicine (IMAGE)

Indiana University School of Medicine

Paul Kwo, M.D., Indiana University School of Medicine

Caption

Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal the Lancet. The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment’s effectiveness when given for 48 weeks in one treatment arm of the study.

Credit

Indiana University School of Medicine

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.